MazzaferriE.L., JhiangSM.Long term impact of initial surgical and medical therapy on papillary and follicular cancer.Am J Med1994: 97: 418–28
2.
LohK.C., GreenspanF.S., GeeL., MillerT.R., YeoPPB.Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas, a retrospective analysis of 700 patients.J Clin Endocrinol Metab1997; 82: 3553–62
3.
TeppoL., HakulinenT. and The Eurocare Working Group. Variation of survival in adult patients with thyroid cancer in Europe.Eur J Cancer1998; 34: 2248–52
4.
VanderpumpM.P.J., AlexanderL., ScarpelloJ.H.B., ClaytonRN.An audit of the management of thyroid cancer in a district general hospital.Clin Endocrinol1998; 48: 419–24
OszataM., SuzukiS., MiyamotoT., LiuR.T., Fierro-RenoyF., DeGrootLJ.Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer.J Clin Endocrinol Metab1994; 79: 98–105
10.
RobbinsR.J., TuttleM., SharafR.N.Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.J Clin Endocrinol Metab2001; 88: 619–25
11.
ColemanP.M., BabbP., DamieckiP.G.Cancer Survival Trends in England and Wales 1971–1995: Deprivation and NHS Region (Series SMPS, no. 61).London: Stationery Office, 1999: 471–8